ECSP099499A - Compuesto [1, 2, 3]-benzotriazinona sustituido en 3 para incrementar las respuestas sinápticas glutamatérgicas - Google Patents

Compuesto [1, 2, 3]-benzotriazinona sustituido en 3 para incrementar las respuestas sinápticas glutamatérgicas

Info

Publication number
ECSP099499A
ECSP099499A EC2009009499A ECSP099499A ECSP099499A EC SP099499 A ECSP099499 A EC SP099499A EC 2009009499 A EC2009009499 A EC 2009009499A EC SP099499 A ECSP099499 A EC SP099499A EC SP099499 A ECSP099499 A EC SP099499A
Authority
EC
Ecuador
Prior art keywords
compound
treatment
benzotriazinone
replaced
increase
Prior art date
Application number
EC2009009499A
Other languages
English (en)
Inventor
Alexis Cordi
Gary Rogers
Rudolf Mueller
Original Assignee
Servier Lab
Cortex Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Cortex Pharma Inc filed Critical Servier Lab
Publication of ECSP099499A publication Critical patent/ECSP099499A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta invención se refiere a la prevención y tratamiento de insuficiencia cerebral, incluyendo incremento del funcionamiento de receptores en las sinapsis en las redes cerebrales responsables de comportamientos de orden superior. Estas redes cerebrales están implicadas en las capacidades cognitivas relacionadas con la alteración de la memoria, tal como se observa en una variedad de demencias, y en desequilibrios de la actividad neuronal entre diferentes regiones cerebrales, como se sugiere en trastornos tales como la enfermedad de Parkinson, esquizofrenia y trastornos afectivos. En un aspecto particular, la presente invención se refiere a un compuesto útil para el tratamiento de dichas condiciones, y a métodos para utilizar este compuesto para dicho tratamiento.
EC2009009499A 2007-01-03 2009-07-07 Compuesto [1, 2, 3]-benzotriazinona sustituido en 3 para incrementar las respuestas sinápticas glutamatérgicas ECSP099499A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87850307P 2007-01-03 2007-01-03
US92143307P 2007-04-02 2007-04-02
PCT/US2007/026416 WO2008085506A1 (en) 2007-01-03 2007-12-28 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses

Publications (1)

Publication Number Publication Date
ECSP099499A true ECSP099499A (es) 2009-10-30

Family

ID=39608956

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009499A ECSP099499A (es) 2007-01-03 2009-07-07 Compuesto [1, 2, 3]-benzotriazinona sustituido en 3 para incrementar las respuestas sinápticas glutamatérgicas

Country Status (37)

Country Link
US (1) US8173644B2 (es)
EP (1) EP2144506B1 (es)
JP (1) JP5139446B2 (es)
CN (1) CN101616592B (es)
AP (1) AP2502A (es)
AR (1) AR064740A1 (es)
AT (1) ATE527269T1 (es)
AU (1) AU2007342365B2 (es)
BR (1) BRPI0720749A2 (es)
CA (1) CA2674460C (es)
CR (1) CR10906A (es)
CU (1) CU23804B7 (es)
CY (1) CY1112493T1 (es)
DK (1) DK2144506T3 (es)
EA (1) EA017437B1 (es)
EC (1) ECSP099499A (es)
ES (1) ES2374995T3 (es)
GE (1) GEP20125438B (es)
GT (1) GT200900189A (es)
HN (1) HN2009001268A (es)
HR (1) HRP20110970T1 (es)
IL (1) IL199651A (es)
MA (1) MA31160B1 (es)
ME (1) ME00819B (es)
MX (1) MX2009007242A (es)
MY (1) MY154877A (es)
NI (1) NI200900131A (es)
NZ (1) NZ578293A (es)
PL (1) PL2144506T3 (es)
PT (1) PT2144506E (es)
RS (1) RS52108B (es)
SG (1) SG163545A1 (es)
SI (1) SI2144506T1 (es)
SV (1) SV2009003322A (es)
TN (1) TN2009000277A1 (es)
WO (1) WO2008085506A1 (es)
ZA (1) ZA200904826B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101626686A (zh) * 2007-01-03 2010-01-13 科泰克斯药品公司 用于提高谷氨酸性突触反应的3-取代基-1,2,3-苯并三嗪酮类化合物
WO2008143963A1 (en) * 2007-05-17 2008-11-27 Cortex Pharmaceuticals, Inc. Di-substituted amides for enhancing glutamatergic synaptic responses
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
US8263591B2 (en) 2007-08-10 2012-09-11 Cortex Pharmaceuticals, Inc. Bicyclic amides for enhancing glutamatergic synaptic responses
US20110257186A1 (en) * 2010-04-15 2011-10-20 Staubli Ursula V Compositions and methods for treating visual disorders
WO2013075624A1 (zh) 2011-11-22 2013-05-30 北京哈三联科技股份有限公司 甘氨酸重摄取抑制剂及其应用
FR3019464B1 (fr) * 2014-04-07 2016-05-06 Servier Lab Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
FR3034019B1 (fr) 2015-03-26 2017-03-17 Servier Lab Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent
CA2988572A1 (en) 2015-06-26 2016-12-29 Takeda Pharmaceutical Company Limited 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
EP3436021A4 (en) 2016-03-29 2019-11-06 RespireRx Pharmaceuticals Inc. COMPOSITIONS AND METHODS FOR TREATING ATTENTION DEFICIT DISORDER
CN106226509B (zh) * 2016-08-12 2019-09-06 中国人民解放军第四军医大学 一种在小鼠前扣带回皮层诱发dse现象的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723436A (en) * 1971-02-25 1973-03-27 Sun Oil Co Process for aromatic lactams
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
FR2597103B1 (fr) * 1986-04-15 1988-12-16 Provesan Sa Procede de preparation de derives d'oxazinobenzothiazine 6,6-dioxyde
EP1367056A1 (en) 1992-07-24 2003-12-03 The Regents Of The University Of California Drugs that enhance synaptic responses mediated by AMPA receptors
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
ATE174915T1 (de) * 1994-10-31 1999-01-15 Merck Patent Gmbh Benzylpiperidinderivate mit hoher affinität zu bindungsstellen von aminosäure-rezeptoren
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
AU4416197A (en) * 1996-09-17 1998-04-14 Regents Of The University Of California, The Positive ampa receptor modulation to enhance brain neurotrophic factor expression
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
US5985871A (en) 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
CN1293665A (zh) 1998-02-18 2001-05-02 神经研究公司 新化合物及其用作阳性ampa受体调节剂
US6713474B2 (en) * 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US6303542B1 (en) * 2000-08-18 2001-10-16 Rohm And Haas Company Herbicidal 3-substituted-phenyl-1,2,3-benzotriazin-4-ones
WO2003045315A2 (en) * 2001-11-26 2003-06-05 Cortex Pharmaceuticals, Inc. Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses
JP2003238555A (ja) * 2002-02-20 2003-08-27 Sumitomo Pharmaceut Co Ltd 細胞死抑制剤
AUPS255202A0 (en) 2002-05-27 2002-06-13 Monash University Agents and methods for the treatment of disorders associated with motor neuron degeneration
EP1592464A4 (en) * 2003-01-13 2011-03-09 Cortex Pharma Inc METHOD OF TREATING COGNITIVE DECLINE FROM LACK OF SLEEP AND STRESS
GB0317482D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
CN101626686A (zh) 2007-01-03 2010-01-13 科泰克斯药品公司 用于提高谷氨酸性突触反应的3-取代基-1,2,3-苯并三嗪酮类化合物
WO2008143963A1 (en) * 2007-05-17 2008-11-27 Cortex Pharmaceuticals, Inc. Di-substituted amides for enhancing glutamatergic synaptic responses
US8263591B2 (en) 2007-08-10 2012-09-11 Cortex Pharmaceuticals, Inc. Bicyclic amides for enhancing glutamatergic synaptic responses
EP2195303A4 (en) * 2007-09-20 2011-07-20 Cortex Pharma Inc 3-SUBSTITUTED 1,2,3-TRIAZIN-4-ONE AND 3-SUBSTITUTED 1,3-PYRIMIDIONE FOR INCREASING GLUTAMATERGIC SYNAPTIC REACTIONS

Also Published As

Publication number Publication date
AR064740A1 (es) 2009-04-22
CU23804B7 (es) 2012-03-15
EA017437B1 (ru) 2012-12-28
CA2674460A1 (en) 2008-07-17
PT2144506E (pt) 2011-12-21
EP2144506A4 (en) 2010-05-05
DK2144506T3 (da) 2012-03-05
PL2144506T3 (pl) 2012-04-30
NZ578293A (en) 2012-01-12
GT200900189A (es) 2011-08-02
US20100137295A1 (en) 2010-06-03
MX2009007242A (es) 2009-09-02
ZA200904826B (en) 2010-09-29
IL199651A0 (en) 2010-04-15
CY1112493T1 (el) 2015-12-09
RS52108B (sr) 2012-08-31
HK1140105A1 (en) 2010-10-08
AP2502A (en) 2012-10-23
IL199651A (en) 2015-08-31
HN2009001268A (es) 2011-12-27
CU20090117A7 (es) 2011-10-05
GEP20125438B (en) 2012-03-26
US8173644B2 (en) 2012-05-08
CA2674460C (en) 2014-07-15
CR10906A (es) 2009-10-23
NI200900131A (es) 2010-03-11
ATE527269T1 (de) 2011-10-15
AU2007342365A1 (en) 2008-07-17
SV2009003322A (es) 2010-02-05
WO2008085506A1 (en) 2008-07-17
TN2009000277A1 (en) 2010-10-18
SI2144506T1 (sl) 2012-01-31
CN101616592A (zh) 2009-12-30
EP2144506A1 (en) 2010-01-20
SG163545A1 (en) 2010-08-30
JP2010514838A (ja) 2010-05-06
HRP20110970T1 (hr) 2012-01-31
AU2007342365B2 (en) 2012-11-15
MY154877A (en) 2015-08-14
EA200900925A1 (ru) 2009-12-30
JP5139446B2 (ja) 2013-02-06
AP2009004931A0 (en) 2009-08-31
CN101616592B (zh) 2013-06-05
ME00819B (me) 2012-03-20
ES2374995T3 (es) 2012-02-23
EP2144506B1 (en) 2011-10-05
BRPI0720749A2 (pt) 2014-01-14
MA31160B1 (fr) 2010-02-01

Similar Documents

Publication Publication Date Title
ECSP099499A (es) Compuesto [1, 2, 3]-benzotriazinona sustituido en 3 para incrementar las respuestas sinápticas glutamatérgicas
TN2009000278A1 (en) 3-substituted-[1,2,3] benzotriazinone compounds for enhancing glutamatergic synaptic responses
CR20130339A (es) Nuevos derivados heterocíclicos y su uso en el tratamiento de desordenes neurológicos
BRPI0919920A2 (pt) compostos para tratamento de doenças e desordens oftálmicas
CL2013001073A1 (es) Compuestos derivados de 6-amino-nicotinamidas sustituidas, como moduladores de kcnq2/3; composicion farmaceutica que los comprende, util para el tratamiento y/o profilaxis de trastornos y/o enfermedades seleccionadas de dolor, epilepsia, ansiedad, enfermedades cognitivas, entre otras.
EA201491534A1 (ru) Ингибиторы бета-секретазы
CL2012001673A1 (es) Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras.
JO3070B1 (ar) عوامل لمعالجة إضطرابات تتضمن تعديل مستقبلات الريانودين
EA201401350A1 (ru) Бензимидазолы, модулирующие tnf-альфа
PL2318035T3 (pl) Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
MX2018011453A (es) Moduladores alostericos de receptores de acetilcolina nicotinicos.
WO2013029060A3 (en) Compositions and methods for treating neurodegenerative disease
CL2012003212A1 (es) Formas cristalinas i y ii de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida monohidratado; procedimientos de preparacion; composicion farmaceutica; su procedimiento de preparacion; y su uso para el tratamiento de trastornos tales como trastorno por deficit de atencion y enfermedad de parkinson.
EP2750606A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF NEUROLOGICAL AND NEURODEEGENERATIVE DISEASES, DISORDERS AND RELATED METHODS
UY34991A (es) Inhibidores de la beta-secretasa
BR0214425A (pt) Compostos carbonilbenzoxazina para aperfeiçoamento de respostas sinápticas glutamatérgicas
EP2566856A4 (en) COMPOUNDS AND METHOD FOR TREATING BRAIN DISEASES
CL2018001633A1 (es) Composiciones de benzofenonas polihidroxiladas y métodos para el tratamiento de trastornos neurodegenerativos
UA93306C2 (ru) Соединение 3-замещенного-[1,2,3]-бензотриазинона для улучшения глутаматергических синаптических реакций
DE602008004563D1 (de) Carbonylamino-derivate zur behandlung von entzündlicher darmerkrankung
BRPI0909659A2 (pt) tratamento para distúrbios relacionados oculares
EP2212246B1 (en) TREATMENT OF NEUROLOGICAL DISORDER
GT200900150A (es) Nuevos compuestos azabiciclicos, un proceso para su preparacion y las composiciones farmaceuticas que los contienen.
WO2014052398A8 (en) Inhibitors of beta-secretase
MX2011008060A (es) Derivados de amida biciclica para mejorar las respuestas sinapticas glutamatergicas.